The literature suggests that KDM5B activates the PI3K/AKT signaling pathway, while reducing KDM5B expression decreases AKT signaling and significantly lowers P110α (a subunit of PI3K) and PIP3 levels, ultimately resulting in the reduced proliferation of prostate cancer cells and suppression of tumorigenesis. This evidence concerns the gene KDM5B and prostate cancer.